(5-chloro-3-methyl-1-benzothien-2-yl)carbonyl chloride | 628725-97-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻吩类
• 英文名称: (5-chloro-3-methyl-1-benzothien-2-yl)carbonyl chloride
• 英文别名: 5-chloro-3-methylbenzo[b]thiophene-2-carbonyl chloride；5-Chloro-3-methyl-1-benzothiophene-2-carbonyl chloride
• CAS: 628725-97-3
• 化学式: C₁₀H₆Cl₂OS
• 分子量: 245.129
• InChiKey: KFVBYLFCLTWVTD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.8
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  45.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (5-chloro-3-methyl-1-benzothien-2-yl)carbonyl chloride 在 O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate 、 N,N-二异丙基乙胺 作用下， 以 N,N-二甲基甲酰胺 、 乙腈 为溶剂， 生成 (3S,3aR,6aS)-4-({(2S)-1-[(5-chloro-3-methyl-1-benzothien-2-yl)carbonyl]pyrrolidin-2-yl}carbonyl)-1-(cyclopropylcarbonyl)-3-methylhexahydropyrrolo[3,2-b]pyrrol-2(1H)-one
  参考文献：
  名称：

  Design and Synthesis of Pyrrolidine-5,5‘-trans-Lactams (5-Oxo-hexahydropyrrolo[3,2-b]pyrroles) as Novel Mechanism-Based Inhibitors of Human Cytomegalovirus Protease. 4. Antiviral Activity and Plasma Stability

  摘要：

  A series of chiral, (S)-proline-alpha-methylpyrrolidine-5,5-trans-lactam serine protease inhibitors has been developed as antivirals of human cytomegalovirus (HCMV). The SAR of the functionality on the proline nitrogen has shown that derivatives of para-substituted phenyl ureas > para-substituted phenyl sulfonamides > para-substituted phenyl carboxamide for activity against HCMV deltaAla protease, producing para-substituted phenyl ureas with single figure nM potency (K-i) against the viral enzyme. The. SAR of the functionality on the lactam nitrogen has defined the steric and electronic requirements for high human plasma stability while retaining good activity against HCMV protease. The combination of high potency against HCMV deltaAla protease and high human plasma stability has produced compounds with significant in vitro antiviral activity against human cytomegalovirus with the 6-hydroxymethyl benzothiazole derivative 72 being equivalent in potency to ganciclovir. The parent benzothiazole 56 had good pharmacokinetics in dogs with 29% bioavailability and good brain and ocular penetration in guinea pigs.

  DOI：

  10.1021/jm030810w
• 作为产物：
  描述：

  5-氯-3-甲基-1-苯并噻吩-2-甲酸 在 N,N-二甲基甲酰胺 草酰氯 作用下， 以 二氯甲烷 为溶剂， 反应 18.0h， 生成 (5-chloro-3-methyl-1-benzothien-2-yl)carbonyl chloride
  参考文献：
  名称：

  AMINO-PYRROLIDINE-AZETIDINE DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS

  摘要：

  揭示了用于治疗各种疾病、综合症、症状和紊乱的化合物、组合物和方法，包括疼痛。这些化合物及其对映体、顺反异构体和药用盐由以下式(I)所代表：其中Y、Z、R1和R2在此处定义。

  公开号：

  US20120101081A1

文献信息

• DI-AZETIDINYL DIAMIDE AS MONOACYLGLYCEROL LIPASE INHIBITORS
  申请人：Connolly Peter J.

  公开号：US20120058986A1

  公开（公告）日：2012-03-08

  Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds are represented by Formula (I) as follows: wherein Q and Z are defined herein.

  揭示了用于治疗各种疾病、综合症、症状和障碍的化合物、组合物和方法，包括疼痛。这些化合物由以下式（I）表示： 其中Q和Z在此处定义。
• OXOPIPERAZINE-AZETIDINE AMIDES AND OXODIAZEPINE-AZETIDINE AMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS
  申请人：Connolly Peter J.

  公开号：US20120077797A1

  公开（公告）日：2012-03-29

  Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds, and enantiomers, diastereomers, and pharmaceutically acceptable salts thereof, are represented by Formula (Ia) and Formula (Ib) as follows: wherein Y, Z, and n are defined herein; and wherein Y b and Z b are as defined herein.

  本文披露了用于治疗各种疾病、综合症、状况和障碍，包括疼痛的化合物、组合物和方法。这些化合物及其对映体、二对映体和药学上可接受的盐由以下的化学式(Ia)和化学式(Ib)表示：其中Y、Z和n在此定义；以及其中Yband Zbare如此定义。
• AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS
  申请人：Janssen Pharmaceutica NV

  公开号：US20130102585A1

  公开（公告）日：2013-04-25

  Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds are represented by Formula (I) as follows: wherein Y, Z, R 1 , and s are defined herein.

  本发明涉及化合物、组合物和治疗各种疾病、综合症、病况和障碍的方法，包括疼痛。这些化合物由以下式子（I）所表示：其中，Y、Z、R1和s在此被定义。
• DI-AZETIDINYL DIAMIDE AS MONOACYLGLCEROL LIPASE INHIBITORS
  申请人：Janssen Pharmaceutica, NV

  公开号：US20130196969A1

  公开（公告）日：2013-08-01

  Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds are represented by Formula (I) as follows: wherein Q and Z are defined herein.

  本发明涉及一种治疗各种疾病、综合征、病况和障碍，包括疼痛的化合物、组合物和方法。这些化合物由以下式子（I）表示：其中Q和Z在此定义。
• US8362000B2
  申请人：——

  公开号：US8362000B2

  公开（公告）日：2013-01-29